Akèy › Obèsite › Missouri › Kansas City
Etid klinik pou Obèsite nan Kansas City, MO
11 etid pou Obèsite ap chèche patisipan nan sit nan ak bò kote Kansas City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Ap rekriteFaz 3
- Alliance for Multispecialty Research - Kansas City, Kansas City
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Ap rekriteFaz 3
- Alliance for Multispecialty Research - Kansas City, Kansas City
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Ap rekriteFaz 3
- Alliance for Multispecialty Research - Kansas City, Kansas City
- Kansas City Veterans Affairs Medical Center, Kansas City
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Ap rekriteFaz 3
- Research Site, Kansas City
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Ap rekriteFaz 3
- Research Site, Kansas City
- Research Site, Kansas City
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Ap rekriteFaz 3
- Saint Luke's Hospital of Kansas City, Kansas City
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Ap rekriteFaz 3
- Kansas City VA Medical Center, Kansas City
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Ap rekriteFaz 3
- Research Site, Kansas City
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Ap rekriteFaz 3
- Clinical Research Consultants, JCCT Co, Kansas City
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
Ap rekriteFaz 1
- MBX Biosciences Investigational Site, Kansas City
Social Determinants and a Diabetes Prevention Program Tailored for African Americans
Ap rekriteFaz 2Volontè an sante akeyi
- University Health, Kansas City
- University of Missouri-Kansas City, Kansas City
Etid Obèsite nan lòt vil
- Houston, TX43 etid
- Chicago, IL41 etid
- New York City, NY40 etid
- San Antonio, TX40 etid
- Washington, DC33 etid
- Orlando, FL32 etid
- Dallas, TX30 etid
- Boston, MA28 etid
- Las Vegas, NV27 etid
- Miami, FL27 etid
- Baltimore, MD26 etid
- Jacksonville, FL25 etid
Lòt etid nan Kansas City
- Kansè nan tete34 etid
- Kansè Poumon ki pa ti selil31 etid
- Ensifizyans kadyak25 etid
- Kansè (tout kalite)21 etid
- Kansè poumon19 etid
- Kansè kolorektal16 etid
- Kansè Metastatik15 etid
- Leksemi mieloïd egi15 etid
- Kansè pwostat14 etid
- Kansè ovè11 etid
- Dyabèt Tip 211 etid
- Maladi kadyovaskilè11 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.